Results 41 to 50 of about 20,433 (107)

Jaceosidin inhibits cell viability and induces apoptosis in non-small cell lung cancer by inhibiting the Ras/Raf/MEK/ERK and Akt pathways. [PDF]

Oncol Lett
Cao X, Ma C, Wang X, Wang C, Shen L, Wei J, Yang R, Li Y, He X, Chen L.   +9 more
europepmc   +1 more source

Hyperfunctioning distant metastases in high-grade differentiated thyroid carcinoma arising from HRAS-mutated follicular thyroid carcinoma: a case report and literature review. [PDF]

Front Endocrinol (Lausanne)
Park JY, Yoo SW, Kim SS, Hong AR, Yoon JH, Kim HK, Kang HC.   +6 more
europepmc   +1 more source

Cellular plasticity as a therapeutic vulnerability: HNF4α is a key target in lung adenocarcinoma. [PDF]

J Clin Invest
Ho R, Mills JC.
europepmc   +1 more source

IGH::FENDRR and specific KRAS mutations define a novel B-ALL molecular subtype with poor chemotherapy response. [PDF]

Blood
Bendig S, Hartmann AM, Wessels W, Beder T, Kim R, Passet M, Gao Q, Wolgast N, Horns JM, Santos LA, Iben K, Steffen FD, Cantoni L, Kehden B, Chitadze G, Künstner A, Busch H, Bornhauser B, Bourquin JP, Leguay T, Boissel N, Gökbuget N, Iacobucci I, Mullighan CG, Clappier E, Baldus CD, Brüggemann M, Bastian L.   +27 more
europepmc   +1 more source

A case of T-prolymphocytic leukemia harboring RAS mutation. [PDF]

Ann Hematol
Perrone S, Pacitto G, Tirnetta A, Mulargia C, Angelitti MR, Corbingi A, Ortu La Barbera E, Fabiani E, Voso MT, Di Napoli A.   +9 more
europepmc   +1 more source

Targeting ICMT: A promising strategy in cancer treatment (Review). [PDF]

Oncol Lett
Hu J, Xiao Y, Tang J.
europepmc   +1 more source

Pleomorphic Carcinoma With EGFR and Concomitant Mutations Transformed From Lung Adenocarcinoma: A Case Report. [PDF]

Cancer Rep (Hoboken)
Akazawa Y, Sato T, Yagami Y, Kesen Y, Furo T, Watanabe A, Endo J, Nakano M, Kurata H, Matsuo H, Nakahara Y, Sasaki J, Naoki K.   +12 more
europepmc   +1 more source

Heterogeneous nuclear ribonucleoprotein K in cancer biology and its therapeutic applications (Review). [PDF]

Mol Med Rep
Qin Y, Zhou Y.
europepmc   +1 more source

Efficacy and safety signals from early-phase studies of KRAS inhibition in pancreatic cancer. [PDF]

Sci Rep
Tiede KOM, Teixeira MF, Moura M, Chiaini O, Moura F, Sonbol MB, Borad M, Bekaii-Saab T, Junior PLSU.   +8 more
europepmc   +1 more source

Hypoxic CAF studies unveil PTHrP‑vitamin D‑RAS axis as pivotal in the CAF. [PDF]

Oncol Rep
Nakajo S, Uemura M, Kusafuka H, Osaki M, Kusunoki C, Takiguchi N, Takeda M, Sekido Y, Hata T, Hamabe A, Ogino T, Miyoshi N, Tei M, Kagawa Y, Yamamoto H, Doki Y, Eguchi H.   +16 more
europepmc   +1 more source